M J Walport|D A Isenberg - JoVE Visualize

Showing results (461-470 of 557) with videos related to

Pageof 56

Sort By:

British Journal of Rheumatology|June 1, 1988

Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogueD A Yardumian, D A Isenberg, M Rustin, et al.

Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2001

Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient miceM G Robson, H T Cook, M Botto, et al.

Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1998

Multiple lupus susceptibility loci map to chromosome 1 in BXSB miceM B Hogarth, J H Slingsby, P J Allen, et al.

Lupus|January 17, 2003

Disturbances in peripheral blood B cell subpopulations in autoimmune patientsK N Potter, C I Mockridge, A Rahman, et al.

Lupus|August 30, 2003

The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosusR L Bates, S J Payne, S L Drury, et al.

International Journal of Immunopharmacology|January 1, 1981

Cyclosporin A for the treatment of systemic lupus erythematosusD A Isenberg, M L Snaith, W J Morrow, et al.

Clinical and Experimental Immunology|June 17, 2005

Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patientsM R J Green, A S M Kennell, M J Larche, et al.

Annals of the Rheumatic Diseases|February 1, 1992

Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosusA J MacGregor, V B Dhillon, A Binder, et al.

Clinical and Experimental Immunology|November 1, 1987

Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosusJ R Batchelor, A H Fielder, M J Walport, et al.

Kidney International|August 1, 1996

Molecular basis of hereditary C1q deficiency associated with SLE and IgA nephropathy in a Turkish familyR Topaloglu, A Bakkaloglu, J H Slingsby, et al.

Pageof 56

Showing results (461-470 of 557) with videos related to

Sort By:

Pageof 56

British Journal of Rheumatology|June 1, 1988

Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogueD A Yardumian, D A Isenberg, M Rustin, et al.

Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2001

Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient miceM G Robson, H T Cook, M Botto, et al.

Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1998

Multiple lupus susceptibility loci map to chromosome 1 in BXSB miceM B Hogarth, J H Slingsby, P J Allen, et al.

Lupus|January 17, 2003

Disturbances in peripheral blood B cell subpopulations in autoimmune patientsK N Potter, C I Mockridge, A Rahman, et al.

Lupus|August 30, 2003

The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosusR L Bates, S J Payne, S L Drury, et al.

International Journal of Immunopharmacology|January 1, 1981

Cyclosporin A for the treatment of systemic lupus erythematosusD A Isenberg, M L Snaith, W J Morrow, et al.

Clinical and Experimental Immunology|June 17, 2005

Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patientsM R J Green, A S M Kennell, M J Larche, et al.

Annals of the Rheumatic Diseases|February 1, 1992

Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosusA J MacGregor, V B Dhillon, A Binder, et al.

Clinical and Experimental Immunology|November 1, 1987

Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosusJ R Batchelor, A H Fielder, M J Walport, et al.

Kidney International|August 1, 1996

Molecular basis of hereditary C1q deficiency associated with SLE and IgA nephropathy in a Turkish familyR Topaloglu, A Bakkaloglu, J H Slingsby, et al.

Pageof 56